250 related articles for article (PubMed ID: 27602580)
1. Correlation between positron emission tomography and Cerenkov luminescence imaging in vivo and ex vivo using 64Cu-labeled antibodies in a neuroblastoma mouse model.
Maier FC; Schmitt J; Maurer A; Ehrlichmann W; Reischl G; Nikolaou K; Handgretinger R; Pichler BJ; Thaiss WM
Oncotarget; 2016 Oct; 7(41):67403-67411. PubMed ID: 27602580
[TBL] [Abstract][Full Text] [Related]
2. Comparative immuno-Cerenkov luminescence and -PET imaging enables detection of PSMA
Maier FC; Wild AM; Kirchen N; Holm F; Fuchs K; Schwenck J; Maurer A; Wiehr S
Appl Radiat Isot; 2019 Jan; 143():149-155. PubMed ID: 30445280
[TBL] [Abstract][Full Text] [Related]
3. Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-Based PET Radiotracers.
D'Souza JW; Hensley H; Doss M; Beigarten C; Torgov M; Olafsen T; Yu JQ; Robinson MK
J Nucl Med; 2017 Jan; 58(1):175-180. PubMed ID: 27539844
[TBL] [Abstract][Full Text] [Related]
4. Cerenkov luminescence imaging of medical isotopes.
Ruggiero A; Holland JP; Lewis JS; Grimm J
J Nucl Med; 2010 Jul; 51(7):1123-30. PubMed ID: 20554722
[TBL] [Abstract][Full Text] [Related]
5. Intratherapeutic biokinetic measurements, dosimetry parameter estimates, and monitoring of treatment efficacy using cerenkov luminescence imaging in preclinical radionuclide therapy.
Timmermand OV; Tran TA; Strand SE; Axelsson J
J Nucl Med; 2015 Mar; 56(3):444-9. PubMed ID: 25655628
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of 89Zr-rituximab tracer by Cerenkov luminescence imaging and correlation with PET in a humanized transgenic mouse model to image NHL.
Natarajan A; Habte F; Liu H; Sathirachinda A; Hu X; Cheng Z; Nagamine CM; Gambhir SS
Mol Imaging Biol; 2013 Aug; 15(4):468-75. PubMed ID: 23471750
[TBL] [Abstract][Full Text] [Related]
7. Cerenkov Luminescence Imaging (CLI) for cancer therapy monitoring.
Xu Y; Liu H; Chang E; Jiang H; Cheng Z
J Vis Exp; 2012 Nov; (69):e4341. PubMed ID: 23183774
[TBL] [Abstract][Full Text] [Related]
8. (68)Ga-labeled 3PRGD2 for dual PET and Cerenkov luminescence imaging of orthotopic human glioblastoma.
Fan D; Zhang X; Zhong L; Liu X; Sun Y; Zhao H; Jia B; Liu Z; Zhu Z; Shi J; Wang F
Bioconjug Chem; 2015 Jun; 26(6):1054-60. PubMed ID: 25853280
[TBL] [Abstract][Full Text] [Related]
9. Multimodal imaging with (18)F-FDG PET and Cerenkov luminescence imaging after MLN4924 treatment in a human lymphoma xenograft model.
Robertson R; Germanos MS; Manfredi MG; Smith PG; Silva MD
J Nucl Med; 2011 Nov; 52(11):1764-9. PubMed ID: 21994410
[TBL] [Abstract][Full Text] [Related]
10. Quantification of Cerenkov Luminescence Imaging (CLI) Comparable With 3-D PET Standard Measurements.
Habte F; Natarajan A; Paik DS; Gambhir SS
Mol Imaging; 2018; 17():1536012118788637. PubMed ID: 30043654
[TBL] [Abstract][Full Text] [Related]
11. Proof-of-concept study of monitoring cancer drug therapy with cerenkov luminescence imaging.
Xu Y; Chang E; Liu H; Jiang H; Gambhir SS; Cheng Z
J Nucl Med; 2012 Feb; 53(2):312-317. PubMed ID: 22241909
[TBL] [Abstract][Full Text] [Related]
12. Cerenkov Luminescence Imaging for Radiation Dose Calculation of a ⁹⁰Y-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Lohrmann C; Zhang H; Thorek DL; Desai P; Zanzonico PB; O'Donoghue J; Irwin CP; Reiner T; Grimm J; Weber WA
J Nucl Med; 2015 May; 56(5):805-11. PubMed ID: 25840974
[TBL] [Abstract][Full Text] [Related]
13. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.
Elsässer-Beile U; Reischl G; Wiehr S; Bühler P; Wolf P; Alt K; Shively J; Judenhofer MS; Machulla HJ; Pichler BJ
J Nucl Med; 2009 Apr; 50(4):606-11. PubMed ID: 19289418
[TBL] [Abstract][Full Text] [Related]
14. 64Cu-p-NH2-Bn-DOTA-hu14.18K322A, a PET radiotracer targeting neuroblastoma and melanoma.
Vavere AL; Butch ER; Dearling JL; Packard AB; Navid F; Shulkin BL; Barfield RC; Snyder SE
J Nucl Med; 2012 Nov; 53(11):1772-8. PubMed ID: 23064212
[TBL] [Abstract][Full Text] [Related]
15. Intraoperative imaging of positron emission tomographic radiotracers using Cerenkov luminescence emissions.
Holland JP; Normand G; Ruggiero A; Lewis JS; Grimm J
Mol Imaging; 2011 Jun; 10(3):177-86, 1-3. PubMed ID: 21496448
[TBL] [Abstract][Full Text] [Related]
16. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
17. PET Imaging of VEGFR-2 Expression in Lung Cancer with 64Cu-Labeled Ramucirumab.
Luo H; England CG; Graves SA; Sun H; Liu G; Nickles RJ; Cai W
J Nucl Med; 2016 Feb; 57(2):285-90. PubMed ID: 26541778
[TBL] [Abstract][Full Text] [Related]
18. In situ lymphoma imaging in a spontaneous mouse model using the Cerenkov Luminescence of F-18 and Ga-67 isotopes.
Ritter Z; Zámbó K; Balogh P; Szöllősi D; Jia X; Balázs Á; Taba G; Dezső D; Horváth I; Alizadeh H; Tuch D; Vyas K; Hegedűs N; Kovács T; Szigeti K; Máthé D; Schmidt E
Sci Rep; 2021 Dec; 11(1):24002. PubMed ID: 34907289
[TBL] [Abstract][Full Text] [Related]
19. The ionic charge of copper-64 complexes conjugated to an engineered antibody affects biodistribution.
Dearling JL; Paterson BM; Akurathi V; Betanzos-Lara S; Treves ST; Voss SD; White JM; Huston JS; Smith SV; Donnelly PS; Packard AB
Bioconjug Chem; 2015 Apr; 26(4):707-17. PubMed ID: 25719414
[TBL] [Abstract][Full Text] [Related]
20. Intrinsically radioactive [64Cu]CuInS/ZnS quantum dots for PET and optical imaging: improved radiochemical stability and controllable Cerenkov luminescence.
Guo W; Sun X; Jacobson O; Yan X; Min K; Srivatsan A; Niu G; Kiesewetter DO; Chang J; Chen X
ACS Nano; 2015 Jan; 9(1):488-95. PubMed ID: 25549258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
